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Incident Vertebral Fractures and Risk Factors in the First
Three Years Following Glucocorticoid Initiation Among
Pediatric Patients With Rheumatic Disorders
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ABSTRACT
Vertebral fractures are an important yet underrecognized manifestation of osteoporosis in children with chronic, glucocorticoidtreated illnesses. Our goal was to determine the incidence and clinical predictors of vertebral fractures in the 3 years following
glucocorticoid initiation among pediatric patients with rheumatic disorders. Incident vertebral fractures were evaluated according
to the Genant semiquantitative method on lateral radiographs at baseline and then annually in the 3 years following glucocorticoid
initiation. Extended Cox models were used to assess the association between vertebral fractures and clinical risk predictors. A total of
134 children with rheumatic disorders were enrolled in the study (mean  standard deviation (SD) age 9.9  4.4 years; 65% girls). The
unadjusted vertebral fracture incidence rate was 4.4 per 100 person-years, with a 3-year incidence proportion of 12.4%. The highest
annual incidence occurred in the ﬁrst year (6.0%; 95% conﬁdence interval (CI) 2.9% to 11.7%). Almost one-half of the patients with
fractures were asymptomatic. Every 0.5 mg/kg increase in average daily glucocorticoid (prednisone equivalents) dose was associated
with a twofold increased fracture risk (hazard ratio (HR) 2.0; 95% CI 1.1 to 3.5). Other predictors of increased vertebral fracture risk
included: (1) increases in disease severity scores between baseline and 12 months; (2) increases in body mass index Z-scores in the
ﬁrst 6 months of each 12-month period preceding the annual fracture assessment; and (3) decreases in lumbar spine bone mineral
density Z-scores in the ﬁrst 6 months of glucocorticoid therapy. As such, we observed that a clinically signiﬁcant number of children
with rheumatic disorders developed incident vertebral fractures in the 3 years following glucocorticoid initiation. Almost one-half of
the children were asymptomatic and thereby would have been undiagnosed in the absence of radiographic monitoring. In addition,
discrete clinical predictors of incident vertebral fractures were evident early in the course of glucocorticoid therapy. © 2015 American
Society for Bone and Mineral Research.
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Introduction

P

ediatric rheumatic disorders span a broad spectrum of
diseases including juvenile idiopathic arthritis (JIA), as well
as systemic rheumatic disorders including juvenile dermatomyositis, systemic lupus erythematosus, and systemic vasculitides.
Despite important advances in therapeutic options for pediatric
patients with rheumatic disorders, glucocorticoids (GC) continue
to be an important treatment for many patients. At the same
time, GC therapy is associated with numerous potential side
effects, including detriments to skeletal health during the critical
period of bone strength development.(1–6)
Vertebral fractures (VF) are a key manifestation of osteoporosis in children and youth with GC-treated rheumatic disorders,
occurring in up to 34% on long-term GC therapy.(1,7–11) We have
shown through prospective surveillance that 7% of children will
have prevalent VF in the ﬁrst few weeks of GC therapy,(12) and
that 6% will have incident VF by 12 months following GC
initiation.(13) We have also shown that children with incident VF
at 12 months had greater increases in body mass index (BMI)
Z-scores and decreases in bone mineral density (BMD) Z-scores
in the ﬁrst 6 months of GC therapy,(13) suggesting that early
bone and body composition changes may signal which pediatric
patients will develop VF following GC initiation.
At the same time, a number of questions about the natural
history and clinical predictors of VF in this setting remained
unanswered. For example, it is not known whether the incidence
of VF continues to increase over time following GC initiation, and
at what time point the VF incidence reaches its peak. Questions
also remain about the severity of bone morbidity due to VF over
the longer-term and whether readily measurable clinical
predictors are evident that can alert clinicians to those children
at greatest risk for VF in the years following GC initiation.
Understanding these issues will facilitate the development of
logical monitoring strategies that target at-risk patients and
identify the best candidates for intervention. The purpose of this
report was to determine the incidence of VF in pediatric patients
with GC-treated rheumatic disorders in the 3 years following GC
initiation, to describe the pattern (time point, location,
symptomatology, and severity) of incident VF, and to elucidate
clinical predictors of 3-year incident VF.

children 16 years with rheumatic disorders were targeted for
enrolment within 30 days of GC initiation and followed for
3 years. Patients were excluded from the study if they had
previously taken GC for the treatment of their underlying
disease. Patients were also excluded if they had received
intravenous or oral GC for >14 consecutive days in the
12 months preceding study enrollment to treat any other
medical condition (e.g. asthma), or if they had previously been
treated with an osteoporosis medication (e.g. a bisphosphonate). The cohort was studied every 3 months for 3 years to allow
for accurate clinical data collection. The research ethics board at
each participating institution approved the study and informed
consent/assent was obtained prior to enrollment.

Clinical data
Demographic and clinical data were collected as described.(12)
Height, weight, and BMI (weight [kg] divided by height [m]
squared) were measured at baseline and every 3 months
thereafter. The raw values for height, weight, and BMI were
transformed into age- and gender-matched Z-scores according
to the U.S. Centers for Disease Control and Prevention National
Center for Health Statistics normative database;(14) for children
under 2 years of age, BMI Z-scores were calculated according to
the World Health Organization child growth standards.(15) In
addition, the presence or absence of back pain as reported by
the participant was recorded every 3 months, with recent back
pain deﬁned as pain reported in the 12 months preceding each
annual VF assessment by lateral spine radiograph.
Dietary calcium and vitamin D intake were assessed by a
validated food frequency questionnaire every 3 months.(16)
Calcium and vitamin D intake by supplementation was added to
the dietary intake to arrive at a total daily intake for both
nutrients, which were further classiﬁed as <50% of the agerelated Dietary Reference Intake (DRI), 50% to 100% of the DRI,
and >100% of the DRI.(17) Physical activity was assessed every
3 months using the Habitual Activity Estimation Scale,(12,18) as
described by our group.(12,13) A physician global assessment of
disease activity for each patient was determined every 3 months
on a 10-cm visual analog scale by a pediatric rheumatologist
(where 0 cm ¼ inactive disease and 10 cm ¼ very active
disease).(12,19–21) Methotrexate exposure was expressed as the
average weekly dose (mg/kg) from all routes of administration.

Patients and Methods
Quantification of GC exposure
Data for this study were obtained from children and youth with
rheumatic disorders enrolled in the Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) study. The STOPP
study is part of a prospective, longitudinal observational
research program involving 10 Canadian academic pediatric
centers studying bone health among those with GC-treated
diseases. Details of the STOPP protocol for pediatric patients
with rheumatic disorders have been published.(12,13)

Patients enrolled in the study
The patients enrolled in this study held the following diagnoses:
juvenile dermatomyositis, systemic lupus erythematosus and
related conditions, JIA (excluding systemic arthritis), JIA
(systemic arthritis), systemic vasculitides (excluding Henoch€nlein purpura and Kawasaki disease), and other conditions,
Scho
including juvenile scleroderma (both systemic and localized).
The eligibility criteria for enrollment in the STOPP study have
been described in detail elsewhere for this cohort.(12) In brief,
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The dose of systemic GC therapy (oral and intravenous) received
during the 3-year observation period was determined entirely at
the discretion of the treating rheumatologist. Daily GC doses
and any subsequent changes were documented quarterly by
chart review, patient or parent interview, and review of home GC
diaries. When a patient missed a study visit, a research assistant
called the family by telephone to record GC dose changes. GC
doses were converted to mg/kg in prednisone equivalents. GC
exposure was described in separate analyses as ﬁve timedependent variables up until the date of each child’s VF
assessment, as follows: (1) average daily dose, deﬁned as the
total amount of GC in prednisone equivalents (per body weight)
divided by the total number of days in the observation period;
(2) duration of GC therapy, expressed as the number of days on
GC since initiation; (3) GC dose intensity, deﬁned as the total
amount of GC per body weight divided by the number of days
on GC during the observation period; (4) recent average daily GC
dose (i.e. average daily dose in the 12 months immediately
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preceding each VF X-ray assessment); and (5) recent duration of
GC therapy (also in the 12 months preceding each VF X-ray
assessment).

Vertebral fracture assessment
For each patient, VF were assessed at baseline and then annually
by lateral thoracolumbar spine radiographs. The spine radiographs were scored independently by two pediatric radiologists
according to the modiﬁed Genant semiquantitative method(22)
and a third radiologist resolved any discrepancies. Vertebral
bodies were graded according to the extent of the reduction in
height ratios when the anterior vertebral height was compared
with the posterior height (anterior wedge fracture), middle
height to the posterior height (biconcave fracture), and posterior
height to the posterior height of adjacent vertebral bodies
(crush fracture). The scores corresponded to the following
reductions in height ratios: grade 0 (normal), 20% or less; grade 1
fracture (mild), >20% to 25%; grade 2 fracture (moderate),
>25% to 40%; and grade 3 fracture (severe), >40%. An incident
VF was deﬁned as a new fracture in a previously normal vertebral
body or worsening of an existing VF (i.e. an increase in the
Genant grade by at least 1); for simplicity, such fractures are
referred to as “incident VF.”

Lumbar spine bone mineral density, bone age, and
second metacarpal morphometry
Within 30 days of GC initiation, areal lumbar spine bone mineral
density (LSBMD) was measured in the anterior-posterior
direction at the L-spine (L1–L4) by dual-energy X-ray absorptiometry (DXA) using either Hologic (Hologic Inc. Bedford, MA,
USA) (QDR 4500 3 centers, Discovery 2 centers, Delphi 1 center)
or Lunar Prodigy (GE Lunar Corporation, Madison, WI, USA)
(4 centers) machines at enrollment and every 6 months
thereafter. Machines were cross-calibrated as described.(12)
The raw LSBMD results were converted to Hologic units, and
Z-scores were generated using the Hologic 12.3 normative
database. Radiographs of the left hand and wrist were obtained
at baseline and annually to determine bone age and second
metacarpal percent cortical area Z-scores as described.(12)

Treatment of vertebral fractures during the course of the
study
The treatment of VF that occurred during the course of the study
was at the discretion of the attending physicians in the various
tertiary care centers, and was not dictated by a STOPP-related
treatment protocol. The age of the patient, clinical stage at
which bone-targeted treatment was initiated and the name of
the drug were recorded; however, a detailed analysis of the
rationale for treatment and the response to bone-speciﬁc
therapy in the few patients who received intervention was
beyond the scope of this natural history study.

Statistical analysis
Analyses were conducted using SAS, version 9.3 (SAS Institute
Inc., Cary, NC, USA). Categorical variables were described using
frequency and percentage. Normally distributed continuous
variables were described using mean and standard deviation
(SD). Non-normally distributed continuous variables were
described using median and interquartile range (IQR). Box plots
were used to describe the trajectories of average daily GC
dosage, LSBMD and BMI Z-scores, and disease activity over time.
Journal of Bone and Mineral Research

The person-years incidence rate was calculated as the number
of children with incident VF divided by the sum of the follow-up
time for each child.(23,24) The annual incidence was calculated as
the number of children with incident VF divided by the number
who completed the VF assessment at the end of the annual,
speciﬁed time period. In order to express the 3-year incidence as a
proportion, it was assumed that the children lost to follow-up or
with missing data had the same probability of developing
incident VF over 3 years as observed in the rest of the cohort.
Extended Cox regression models, which allow non-proportional
hazards, recurrent events, and time-varying covariates,(25) were
used to determine the association between incident VF and (1)
time-independent risk factors including age, bone age, pubertal
stage, gender, speciﬁc diagnosis as well as prevalent VF at
baseline, and (2) time-dependent risk factors including GC
exposure as deﬁned above, disease activity, BMI Z-score, LSBMD
Z-score, second metacarpal percent cortical area Z-score, recent
back pain (in the 12 months preceding each VF assessment),
physical activity, and average calcium and vitamin D intake from
diet and supplementation combined. Data were censored at the
point when one of the following occurred ﬁrst: the 36-month
follow-up visit, the last available visit, or when bone-speciﬁc
therapy (such as a bisphosphonate) was instituted for symptomatic VF in accordance with the local standard-of-care. A test for
non-proportional hazards using the Schoenfeld residuals(25) was
performed, and smooth estimates of hazard ratios were
calculated using the method of Therneau and Grambsch.(25) If
the proportional hazards assumption was not rejected at the 0.05
signiﬁcance level, the constant hazard ratio (consistent with the
proportional hazards assumption) was used to reduce the risk of
overﬁtting bias.(26) Robust variance estimators were used to
account for multiple VF assessments on the same patient.
Selection of VF risk factors for inclusion in the ﬁnal models was
guided by clinical judgment and univariate analysis, with the
effects from the extended Cox models expressed as the hazard
ratio (HR), corresponding 95% conﬁdence interval (CI), and the
associated p value.

Results
Clinical characteristics of the cohort
A total of 136 pediatric patients with rheumatic disorders were
enrolled into the study; 2 were excluded because of failure to
undergo a bone health evaluation within 30 days of GC
initiation. The number of children with a valid VF assessment at
the 12-month, 24-month, and 36-month follow-up visits was
118, 105, and 110, respectively. Note, one child received
bisphosphonate therapy at 4 months after GC initiation because
of symptomatic vertebral collapse; this child was included in the
calculation of incident VF in the ﬁrst 12 months following GC
therapy. The reasons for lack of available data on some patients
at each time point are presented in Fig. 1. The clinical proﬁle at
baseline for patients with incomplete data did not differ
signiﬁcantly from those with complete follow-up (data not
shown).
Descriptions of this cohort at baseline and at 12 months
following GC initiation have been published in two
reports.(12,13) In brief, among the 134 patients (mean  SD
age 9.9  4.4 years; 65% girls; 75% Caucasian; 7% with
prevalent VF at baseline), 30 (22%) had juvenile dermatomyositis, 28 (21%) had JIA (excluding systemic arthritis), 26 (20%)
had systemic lupus erythematosus, 22 (16%) JIA (systemic
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(n=4)

Fig. 1. Disposition of patients from baseline to 36 months based on the ability to carry out the vertebral fracture evaluation by lateral spine radiograph.

arthritis), 16 (12%) systemic vasculitis, and 12 (9%) had other
rheumatic disorders (localized scleroderma, n ¼ 10; generalized scleroderma, n ¼ 1; and eosinophilic fasciitis, n ¼ 1). The
baseline VF assessment occurred at a median of 18 days (IQR,
11 to 24) following GC initiation. There were no signiﬁcant
differences for the following studied variables in respect to
race and gender: prevalent and incident VF, LSBMD Z-score,
age, diagnosis, average daily GC dose, BMI Z-score, physical
activity, calcium intake, and vitamin D intake. On the other
hand, the disease activity score at baseline was higher for
boys compared to girls (mean  SD 6.4  5.1 versus 5.1  2.8,
p ¼ 0.011).
For vitamin D daily intake through supplementation and diet
combined at baseline, the mean  SD % of the DRI was
111%  79%. Overall, 48% of children were below the DRI at
baseline. By 36 months, the mean  SD % of the DRI increased to
138%  106% and the % of patients below DRI decreased to
38%. Although there was a statistically signiﬁcant increase in the
total vitamin D intake at 36 months compared to baseline
(p ¼ 0.018), the proportion of children with intakes less than
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100% of the DRI was not different between these two time
points (p ¼ 0.136).
For daily calcium intake through supplementation and diet
combined, at baseline the mean  SD % of the DRI was
246%  165% and 15% of patients fell below the DRI at this
time point. By the end of 36 months, the mean  SD % of the DRI
decreased to 175%  81%; at this time point, only 24% of the
patients were below the DRI. Although there was a statistically
signiﬁcant decline in the total calcium intake between baseline
and 36 months (p < 0.001), the proportion of children with
intakes less than 100% of the DRI was not different between
these two time points (p ¼ 0.123).

The frequency and pattern of incident vertebral fractures
Twenty-nine incident VF (26 thoracic, 3 lumbar) were identiﬁed
in 14 children during the 3 years following GC initiation. Children
with incident VF held the following diagnoses: 6 had juvenile
dermatomyositis, 4 had systemic lupus erythematosus, 2 had
systemic vasculitis, 1 child had JIA (systemic arthritis), and 1 had
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JIA (excluding systemic arthritis). Of those with incident VF, 57%
reported back pain in the preceding 12 months whereas 43%
were asymptomatic. Twenty-eight of the 29 incident VF (97%)
were in previously normal vertebral bodies, whereas only one
was worsening of an existing fracture. Eight of 14 children (57%)
with incident VF had a single fracture; the other 6 children (43%)
had 2 incident VF (n ¼ 3), 3 VF (n ¼ 1), 5 VF (n ¼ 1) or 7 VF (n ¼ 1).
Nine children (64%) had mild VF as the worst grade, 5 (36%) had
moderate fractures, and none had severe fractures. Interestingly,
two patients had one incident VF each after GC cessation (1.1
and 2.8 years following the discontinuation of GC therapy). All
other VF occurred while on GC therapy (Fig. 2A, B).
The unadjusted VF incidence rate was 4.4 per 100 personyears, with a 3-year incidence proportion of 12.4%. Seven
children had VF in the ﬁrst year for an annual incidence of 6.0%
(95% CI 2.9% to 11.7%), 5 children had VF during the second year
(annual incidence 4.8%; 95% CI 2.1% to 10.7%), and 4 children
had VF during the third year (annual incidence 3.6%; 95% CI 1.4%
to 9.0%). Two children had incident VF at two different time
points (i.e. a recurrence of incident VF), whereas the other 12
children had incident VF at just a single time point (i.e. at 12, 24,
or 36 months). One patient with recurrent VF was an 8-year-old
girl with lupus. This patient had her ﬁrst VF at 12 months (grade
2, T12) and the second at 24 months (grade 2, T11). The other
child with recurrent VF was one of the most severely affected in
the cohort. This 9-year-old girl with systemic vasculitis had her
ﬁrst incident VF at 12 months (grade 1, T8) and then additional VF
at 24 months (grade 2 at T4; grade 1 at T6; grade 2 at T7; and
grade 1 at T11 and T12). In addition, the 12-month grade 1 VF at T8
progressed to a grade 2 VF at 24 months.

GC exposure, disease activity, and LSBMD and BMI
Z-score trajectories
The average daily GC dose for the ﬁrst 6 months was high
(mean  SD 0.94  0.84 mg/kg/day; median 0.73; IQR 0.23 to
1.31) and then decreased substantially to 0.23  0.29 mg/kg/day
(median 0.15; IQR 0.04 to 0.30) between 6 and 12 months
following GC initiation. The average daily GC exposure fell
gradually thereafter to 0.06  0.12 mg/kg/day (median 0; IQR 0
to 0.06) between 30 months and 36 months. The median
duration over which children had received daily or intermittent
GC therapy was 578 days (IQR 241 to 869). Among patients in the
overall cohort, 32 (24%) discontinued GC therapy by 12 months,
28 (21%) patients between 12 and 24 months, and 15 (11%)
between 24 and 36 months (59 (44%) children were still on GC
therapy by 36 months) (Fig. 3).
The mean LSBMD Z-score was low compared to the healthy
average at baseline (–0.56  1.18; p < 0.001) and reached its
nadir at 6 months (mean  SD LSBMD Z-score –0.93  1.21). The
LSBMD Z-score increased gradually thereafter with a mean  SD
of –0.66  1.18 at 36 months. Disease activity was high at
baseline (mean  SD disease activity score 5.56  2.75) but
dropped after the initiation of GC therapy. In contrast, the BMI Zscore increased in the ﬁrst 6 months after GC therapy and then
fell gradually.

Risk factors for incident vertebral fractures
The results of the multivariate extended Cox models to identify
factors associated with the risk of incident VF are presented in
Table 1. The multivariate models showed that every 0.5 mg/kg

Fig 2. (A) The severity, frequency and distribution of incident vertebral fractures in children with glucocorticoid-treated rheumatic disorders. (B) The
distribution and frequency of incident vertebral fracture morphology.
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Fig. 3. Description of the 3-year trajectories for glucocorticoid exposure, lumbar spine bone mineral density Z-scores, body mass index Z-scores, and
disease activity.

increase in average daily GC dose was associated with a 95%
increased VF risk (Model 1, HR 1.95; 95% CI 1.08 to 3.51;
p ¼ 0.026). In addition, every 1-month increase in recent
duration of GC treatment was associated with a 22% increased
VF risk (Model 5, HR 1.22; 95% CI 1.08 to 1.36; p ¼ 0.001). GC
intensity, duration of GC therapy, and recent average daily GC
were not signiﬁcantly associated with increased VF risk. All
multivariate models showed that increases in disease activity
between baseline and 12 months, increases in BMI Z-scores in
the ﬁrst 6 of the 12 months preceding each annual VF
assessment, and decreases in BMD Z-scores in the ﬁrst 6 months
of GC therapy were signiﬁcantly associated with an increased
incident VF risk. All multivariate models were adjusted for
speciﬁc underlying diagnosis, as well as age and height Z-scores
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at baseline given their importance as potential confounders. On
the other hand, the following variables were excluded from our
ﬁnal, reported models given their lack of signiﬁcance in the
multivariate regression modeling: calcium and vitamin D intake,
pubertal stage, gender, prevalent VF at baseline, second
metacarpal percent cortical area Z-score, recent back pain,
methotrexate exposure, and physical activity.

Discussion
This study provides novel data on the VF incidence in a cohort of
pediatric patients with GC-treated rheumatic disorders captured
through prospective, annual VF surveillance with a systematic VF
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Table 1. Multivariate Cox Regression Models Assessing the Association Between Potential Risk Factors and Incident Vertebral Fracture
Model 1
Clinical parameters

"GC exposure
"VAS score, baseline to 12 months
"BMI Z-score, in the first 6 months
preceding each annual VF assessment
#LSBMD score, baseline to 6 months

Model 2
p

HR (95% CI)

Average daily GC
dose (0.5 mg/kg)
1.95 (1.08–3.51)
1.38 (1.14–1.66)
3.21 (1.60–6.45)
2.98 (1.10–8.07)

Model 3
p

HR (95% CI)

p

0.03
0.02
<0.01

GC dose intensity
(0.5 mg/kg)
0.97 (0.91–1.02)
1.32 (1.10–1.59)
4.05 (2.13–7.69)

0.22
<0.01
<0.01

Duration of GC
exposure (years)
1.36 (0.80–2.33)
1.31 (1.08–1.58)
3.94 (2.05–7.55)

0.26
0.01
<0.01

0.03

4.17 (1.48–11.77)

0.01

4.29 (1.46–12.60)

0.01

HR (95% CI)

Model 4
Clinical parameter

Model 5
p

HR (95% CI)
a

"GC exposure
"VAS score, baseline to 12 months
"BMI Z-score, in the first 6 months
preceding each annual VF assessment
#LSBMD score, baseline to 6 months

Recent average daily GC
dose (0.5 mg/kg)
1.54 (0.84–2.81)
1.33 (1.10–1.60)
3.42 (1.70–6.88)
3.66 (1.29–10.37)

p

HR (95% CI)
a

0.16
<0.01
<0.01

Recent duration of GC
therapy (months)
1.22 (1.08–1.36)
1.28 (1.04–1.56)
3.26 (1.69–6.29)

<0.01
0.02
<0.01

0.01

4.91 (1.54–15.65)

0.01

a

In the 12 months preceding the annual VF assessment.

assessment protocol. The fact that 14 out of 136 children
sustained at least 1 incident VF (on average, 2.1 VF per child) and
2 children had recurrent, incident VF (including 1 child with a
total of 7 incident VF) highlights the potential for signiﬁcant
bone morbidity in this context. This fact is underscored by our
observation that about one-third of the children with VF had
moderate vertebral collapse. Importantly, the peak annual VF
incidence in our cohort occurred at 12 months following GC
initiation, an outcome which is not surprising given that GC
exposure was highest in the ﬁrst year of therapy, as well as the
known rapidity with which GC exert their deleterious
effects.(27,28) A key ﬁnding was that 43% of patients with
incident VF were asymptomatic (and would have thereby gone
undetected in the absence of routine surveillance), consistent
with other VF surveillance reports in children with GC-treated
leukemia and nephrotic syndrome.(29,30) The potential for VF to
be asymptomatic appears a robust observation with considerable implications for routine monitoring.
Apart from our earlier study describing this cohort to
12 months following GC initiation,(13) there are no other
prospective, longitudinal studies describing the incidence of
VF captured through routine surveillance in pediatric rheumatic
disorders. We previously showed a 6% VF incidence in this
context at 12 months, and noted that symptomatic VF were
present as early as 4 months following GC initiation.(13) A recent,
prospective study by Lim and colleagues(31) (with spine BMD Zscore as the main outcome) reported that 3 of 68 children (4%)
with lupus had asymptomatic VF (VF assessment method not
speciﬁed) over a 2-year observation period when the criteria for
performing a spine radiograph was a LSBMD Z-score  –2 SD
and/or back pain. In our present study, 4 of 26 children with GCtreated lupus (15%) had incident VF in the ﬁrst 2 years when all
children were routinely monitored, and in our overall cohort, 3 of
14 children had incident VF despite LSBMD Z-scores better than
–2 SD and an absence of back pain. Our results highlight the
importance of routine VF surveillance in at-risk children, even
among those with LSBMD Z-scores better than –2 SD and an
absence of back pain.
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We found that a higher daily average dose and longer
duration of GC therapy in the 12 months preceding each annual
VF assessment were associated with an increased risk of incident
VF. As well, readily measurable changes in patients’ clinical
proﬁles also independently predicted increased VF risk, including increases in BMI Z-scores in the ﬁrst 6 months of GC therapy
(and in the ﬁrst 6 months leading up to the annual VF
assessment), decreases in LSBMD Z-scores from baseline to
6 months, and increases in disease activity scores from baseline
to 12 months. These ﬁndings are in line with those from other
studies investigating bone health outcomes in GC-treated
children with rheumatic disorders with different study designs.(1,8,32) Varonos and colleagues(1) conducted a retrospective
study of 23 GC-treated patients with JIA (including 19 with
systemic arthritis) who had at least one VF and compared these
patients to similar-aged children with JIA treated with GC but
without a history of VF. They found children with VF received a
daily GC dose that was 2.3 times higher than those without.
Markula-Patjas and colleagues(32) conducted a cross-sectional
study of 50 adolescents with a history of treatment-resistant
polyarticular JIA for 5 years or systemic arthritis for 3 years.
Results showed that high disease activity, high BMI, and high
cumulative GC dose in the 3 (retrospective) years preceding the
cross-sectional VF assessment were associated with a signiﬁcant
VF risk. In another cross-sectional study of 94 children with a
variety of rheumatic diseases, Nakhla and colleagues(8) documented that cumulative GC dose and higher BMI Z-scores were
associated with the prevalent VF after variable durations of GC
exposure.
The fact that high disease activity is a consistent predictor of
bone morbidity is not surprising, given the deleterious skeletal
effect of proinﬂammatory cytokines such as tumor necrosis
factor alpha (TNF-a) as well as interleukin-1 and interleukin-6.
These cytokines are known to impact the differentiation and
function of osteoblasts and osteoclasts, uncoupling the tightly
regulated bone remodeling cycle causing excessive skeletal
resorption,(33) and by promoting osteoclastogenesis through
action on the osteoclast lineage including RANKL.(34) The other
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consistent predictor of VF (an early predictor) is an increase in
BMI Z-score. Studies of weight gain as a risk factor for fractures in
healthy children have been inconsistent to date;(35–38) however,
none of these studies assessed the relationship between weight
and VF. Our results suggest the predictive increase in BMI Zscores in the ﬁrst 6 months of GC therapy may be a marker of
sensitivity to GC therapy.
Our study highlights the need for a bone health assessment in
at-risk patients that includes not only a DXA-based BMD but also
a lateral thoracolumbar spine radiograph. Having previously
described a baseline VF prevalence of 7% in this context,(12) and
because the earliest report of incident VF has been at 4 months
following GC initiation,(13) it seems reasonable to recommend a
baseline spine radiograph at the time of GC initiation for any
child anticipated to be on GC therapy for 3 months or more. In
addition, a follow-up radiograph at 12 months also appears
justiﬁed given this is the time point of the highest annual VF
incidence, particularly in patients with increases in disease
activity and BMI and decreases in LSBMD Z-scores (the latter two
variables, in the ﬁrst 6 months of GC therapy). These data also
support additional spine radiograph at intervals beyond the ﬁrst
year in those with ongoing need for GC therapy or further
increases in BMI Z-scores.
Given that our data suggest a spine radiograph should be a
key component of the bone health evaluation in at-risk children
and adolescents, it is interesting that the International Society
for Clinical Densitometry recently revised its position statement
on the diagnosis of osteoporosis in children, stating that for
those with a low-trauma VF, BMD-based criteria are no longer
required to diagnose osteoporosis.(39) Our data provide concrete
support for this recommendation, because 8% of children in our
study with at least one incident VF over the 3 year study
period had a LSBMD Z-score > –2 SD. We have also made this
observation in children with leukemia (48% of children with
leukemia and VF at diagnosis had LSBMD Z-scores > –2 SD).(40)
Identifying children with both symptomatic and asymptomatic
vertebral collapse is important, because it provides the clinician
with the opportunity to institute appropriate monitoring and
treatment strategies.
In summary, we have shown the VF incidence is 4.4 per
100 person-years in the 3 years following GC initiation, that
the highest annual incidence of VF is at 12 months, and that
discrete clinical predictors are evident early in the disease
and GC treatment course. These natural history observations
provide important data to support inclusion of a spine
radiograph as part of the routine bone health assessment in
at-risk children.
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